NCT04087681View on ClinicalTrials.gov

Study to Collect Information About Invasive Disease Caused by Extraintestinal Pathogenic Escherichia Coli (EXPECT-1)

CompletedOBSERVATIONAL

Enrollment

4,479

Participants

Timeline

Start Date

September 28, 2019

Primary Completion Date

May 7, 2021

Study Completion Date

June 21, 2021

Conditions

E.Coli Infections

Trial Locations (8)

27701

Duke Clinical Research Institute, Durham

37129

University of Verona, Verona

41013

- Andalusian Public Foundation for Health Research Management in Seville (FISEVI), Seville

50937

UKK Uniclinic Cologne, Cologne

87042

Chu Limoges - Cic, Limoges

Unknown

Duke Clinical Research Institute, Greater Sudbury

- 5-2 Nishikanda, 3-chome

Janssen Pharmaceutical K.K., Tokyo

OX1 2JD

University of Oxford, Oxford

All Listed Sponsors

collaborator

Janssen Research & Development, LLC

INDUSTRY

collaborator

Innovative Medicines Initiative

OTHER

lead

MJM Bonten

OTHER

NCT04087681 - Study to Collect Information About Invasive Disease Caused by Extraintestinal Pathogenic Escherichia Coli (EXPECT-1) | Biotech Hunter | Biotech Hunter